CD1D and neoplasm: Notably, tumor-specific T cell receptor–engineered (TCR-engineered) CD1d-restricted iNKT cells induced robust antitumor responses by simultaneously targeting cancer cells and MDSCs in B16-Ova or MC38-Ova tumor-bearing mice (42).